Terns Pharmaceuticals, Inc.
TERNUnlisted companyTerns Pharmaceuticals, Inc. timeline
- 2021
- 🔔· approximateInitial public offering on Nasdaq
Events of Terns Pharmaceuticals, Inc. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Terns Pharmaceuticals, Inc.
- Acquisitions and changes
- No longer listed: ticker TERN is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).
Market cap history
World rank over time
Rank in USA: #4,070 (Jan 2022) · #3,176 (Dec 2022) · #2,905 (Jul 2023) · #2,685 (Jan 2024) · #106 (Mar 2026)
Mutual funds holding Terns Pharmaceuticals, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC | 11,905 | $1 M | — | 0.38% | — | Mar 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 1 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Markets and events: Terns Pharmaceuticals, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-05-04 23:50 UTC, code D, resumed 04:00 UTC
- 2025-12-08 19:40 UTC, code T3, resumed 20:05 UTC
Fails to deliver
- : 1,007 shares at $52.95
- : 5,224 shares at $52.93
- : 22,564 shares at $52.94
- : 37 shares at $52.83
- : 537 shares at $52.84
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Where Terns Pharmaceuticals, Inc. operates: 1 country#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
Only the headquarters country is on file for Terns Pharmaceuticals, Inc.: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Terns Pharmaceuticals, Inc.🇺🇸 | $4.4 B | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Mar 8, 2026 (last known)
- Profile updated:
- Nov 14, 2026
Figures from value.today research.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Terns Pharmaceuticals, Inc.? Verify and update this profile — free
Show Terns Pharmaceuticals, Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.